A Clinical Study of AK0610

Official title

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of AK0610 in Healthy Chinese Adults.

Overview

The study consists of two parts: dose escalation and expansion. It includes five cohorts in the dose-escalation phase and two expansion cohorts based on pharmacokinetic data.

Detailed description

This study is a Phase I clinical trial that is randomized, double-blind, placebo-controlled, and involves single-dose administration, dose-escalation, and an expansion phase. It evaluates the safety, tolerability, and pharmacokinetic profile of AK0610 in healthy Chinese adults.

The study consists of two parts. The dose-escalation phase includes five cohorts (100 mg i.m.; 300 mg i.m.; 300 mg i.v.; 1000 mg i.v.; 3000 mg i.v.), each consisting of 8 individuals (AK0610: Placebo = 3:1), who are administered doses in sequential increments.

Based on pharmacokinetic data, the dose-escalation phase will be expanded to include two additional dose cohorts (300 mg i.m.; 600 mg i.m.) of 48 individuals each (AK0610: Placebo = 3:1).

Each participant will undergo a Screening Period from Day -29 to Day -1. They will receive one dose on Day 1, an Inpatient Observation Period from Day -1 to Day 8, and a Blinded Follow-Up Period from Day 9 to Day 181. Subjects in the AK0610 group will also enter an open-label period from Day 182 to Day 361.

Interventions

• Drug AK0610 Injection solution
  Active Substance: AK0610 Pharmaceutical Form: Injection solution Route of Administration: Intramuscular injection or intravenous injection.
• Drug Placebo
  Active Substance: Placebo Pharmaceutical Form: Injection Route of Administration: Intramuscular injection or intravenous injection

Primary outcome measures

• Incidence and severity of treatment-emergent adverse events (TEAEs) [Time frame: Up to 361 days]

Secondary outcome measures (11)

• Maximum Observed Serum Concentration (Cmax) of AK0610 [Time frame: Up to 361 days]
• Time to Reach Maximum Observed Serum Concentration (Tmax) of AK0610 [Time frame: Up to 361 days]
• Area Under the serum concentration-time curve from time 0 to the last measurable concentration (AUC₀-t) of AK0610 [Time frame: Up to 361 days]
• Area Under the serum concentration-time curve from time 0 to extrapolated to infinite time (AUC (0-infinity) ) of AK0610 [Time frame: Up to 361 days]
• Terminal Elimination Half Life (t1/2) of AK0610 [Time frame: Up to 361 days]
• Extravascular Clearance (CL/F (intramuscular administration)) of AK0610 [Time frame: Up to 361 days]
• Apparent Volume of Distribution (Vd/F (intramuscular administration)) of AK0610 [Time frame: Up to 361 days]
• CL(IV administration) of AK0610 [Time frame: Up to 361 days]
• Vd (IV administration) of AK0610 [Time frame: Up to 361 days]
• To assess the changes in serum RSV-neutralizing activity after a single intramuscular or intravenous injection of AK0610 in healthy Chinese subjects [Time frame: Up to 361 days]
• To assess the immunogenicity of a single intramuscular or intravenous injection of AK0610 in healthy Chinese subjects. [Time frame: Up to 361 days]

Eligibility criteria

Inclusion criteria

• Participants aged 18 - 50 (both males and females)
• Males weighing ≥50 kg, females weighing ≥45 kg, and BMI 18-28 kg/m2.
• Assessed by the investigator to be in good health with no clinically significant abnormalities.
• Use of highly effective contraception within 1 year of administration.
• Voluntary participation in clinical research and signing of written informed consent.

Exclusion criteria

• Clinically significant cardiovascular, respiratory, hepatic, renal, hematologic (e.g., bleeding disorders), gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric system disorders, or any other condition that, in the opinion of the Investigator, may jeopardize subject safety or validity of the study results, or that may result in the inability of the subject to complete the study in accordance with the protocol.
• Active malignancy and/or a history of malignancy (except for basal cell carcinoma of the skin that has been treated without evidence of recurrence)
• History of congenital or acquired immunodeficiency.
• Acute illness, such as fever, infectious disease, diarrhea, etc., occurring within 1 week prior to the subject's first dose.
• Major surgery within 3 months prior to screening or major surgery planned within 1 year of study drug administration.
• Hypersensitivity to the active ingredient of AK0610 or any excipients.
• Previous history of allergy to biologics or history of severe allergic reaction (e.g. hypotension, dyspnea, severe angioedema) to any drug.
• Human immunodeficiency virus (HIV) antibody positive; hepatitis C virus (HCV) antibody positive or hepatitis B surface antigen (HBsAg) positive; syphilis spirochete antibody positive.
• Systolic blood pressure ≥140 mmHg or <90 mmHg or diastolic blood pressure ≥90 mmHg or <60 mmHg, and pulse <55 or >100 beats/min.
• ECG suggestive of prolonged QTcF (≥450 ms in both women and men). \[QTcF= QT/(RR\^0.33)\]
• Use of any prescription, over-the-counter, herbal, proprietary, or health care product (other than birth control pills) within 14 days prior to study drug administration.
• Have received treatment with immune globulin or other blood products within 6 months prior to study drug administration
• Have received treatment with monoclonal antibodies or other biological products within 6 months prior to administration of study drug.
• Have received a live attenuated vaccination within 1 month prior to study drug administration, has received another vaccination within 14 days, or is scheduled to receive a vaccination within 1 year of study drug administration.
• Received any other investigational drug therapy within 3 months (or 5 half-lives, whichever is longer) prior to study drug administration, or plans to participate in another study within 1 year of study drug administration.
• Participating or have participated in another interventional clinical study of a monoclonal antibody or vaccine against RSV.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Prevention

Study locations

China · 1 center

• The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qi — Jinan

Identifiers

NCT: NCT06996704 · AK0610-2001

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗